Cholesterol and beyond-The role of the mevalonate pathway in cancer biology
A Göbel, M Rauner, LC Hofbauer… - Biochimica et Biophysica …, 2020 - Elsevier
Cancer is a multifaceted global disease. Transformation of a normal to a malignant cell takes
several steps, including somatic mutations, epigenetic alterations, metabolic reprogramming …
several steps, including somatic mutations, epigenetic alterations, metabolic reprogramming …
IL‐17‐producing γδ T cells and innate lymphoid cells
The inflammatory cytokine IL‐17 plays a critical role in immunity to infection and is involved
in the inflammatory pathology associated with certain autoimmune diseases, such as …
in the inflammatory pathology associated with certain autoimmune diseases, such as …
Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer
The increasing evidence that γδ T cells have potent antitumor activity suggests their value in
immunotherapy, particularly in areas of unmet need such as metastatic carcinoma. To this …
immunotherapy, particularly in areas of unmet need such as metastatic carcinoma. To this …
Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl …
CT Morita, C Jin, G Sarikonda… - Immunological reviews, 2007 - Wiley Online Library
Human Vγ2Vδ2 T cells play important roles in mediating immunity against microbial
pathogens and have potent anti‐tumor activity. Vγ2Vδ2 T cells recognize the …
pathogens and have potent anti‐tumor activity. Vγ2Vδ2 T cells recognize the …
[HTML][HTML] Bisphosphonate conjugation for bone specific drug targeting
KB Farrell, A Karpeisky, DH Thamm, S Zinnen - Bone reports, 2018 - Elsevier
Bones provide essential functions and are sites of unique biochemistry and specialized
cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has …
cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has …
Improving the efficiency of Vγ9Vδ2 T-cell immunotherapy in cancer
T Hoeres, M Smetak, D Pretscher… - Frontiers in …, 2018 - frontiersin.org
Increasing immunological knowledge and advances in techniques lay the ground for more
efficient and broader application of immunotherapies. gamma delta (γδ) T-cells possess …
efficient and broader application of immunotherapies. gamma delta (γδ) T-cells possess …
In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients
S Meraviglia, M Eberl, D Vermijlen… - Clinical & …, 2010 - academic.oup.com
The potent anti-tumour activities of γδ T cells have prompted the development of protocols in
which γδ-agonists are administered to cancer patients. Encouraging results from small …
which γδ-agonists are administered to cancer patients. Encouraging results from small …
γδ T cells link innate and adaptive immune responses
W Holtmeier, D Kabelitz - Mechanisms of epithelial defense, 2005 - karger.com
While most T cells use a CD3-associated α/β T cell receptor as antigen recognition structure,
a second population of T cells expresses the alternative γ/δ T cell receptor. γ/δ T cells are a …
a second population of T cells expresses the alternative γ/δ T cell receptor. γ/δ T cells are a …
Novel aspects of mevalonate pathway inhibitors as antitumor agents
M Thurnher, O Nussbaumer, G Gruenbacher - Clinical Cancer Research, 2012 - AACR
The mevalonate pathway for cholesterol biosynthesis and protein prenylation has been
implicated in various aspects of tumor development and progression. Certain classes of …
implicated in various aspects of tumor development and progression. Certain classes of …
Zoledronic acid repolarizes tumour‐associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway
It is unknown whether zoledronic acid (ZA) at clinically relevant doses is active against
tumours not located in bone. Mice transgenic for the activated ErbB‐2 oncogene were …
tumours not located in bone. Mice transgenic for the activated ErbB‐2 oncogene were …